Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.
about
Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug RepositioningRepurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids.Ergosterol isolated from the basidiomycete Pleurotus salmoneostramineus affects Trypanosoma cruzi plasma membrane and mitochondria.Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibitionDrug strategies targeting CYP51 in neglected tropical diseasesLead identification to clinical candidate selection: drugs for Chagas disease.Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversityPopulation pharmacokinetics of benznidazole in adult patients with Chagas disease.Enantiomers of nifurtimox do not exhibit stereoselective anti-Trypanosoma cruzi activity, toxicity, or pharmacokinetic properties.Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.Development and application of a sensitive, phenotypic, high-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotesStructure-based approach to the identification of a novel group of selective glucosamine analogue inhibitors of Trypanosoma cruzi glucokinase.Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps.Chagas disease drug discovery: toward a new era.Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery.Pharmacokinetics of Benznidazole in Healthy Volunteers and Implications in Future Clinical TrialsNovel drug discovery for Chagas disease.Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agentsAssessing anti-T. cruzi candidates in vitro for sterile cidality.Biological factors that impinge on Chagas disease drug development.Trypanocidal Activity of Long Chain Diamines and Aminoalcohols.In vitro drug susceptibility of two strains of the wildlife trypanosome, Trypanosoma copemani: A comparison with Trypanosoma cruziAntitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.Experimental and Clinical Treatment of Chagas Disease: A Review.A Metagenomic Analysis of Bacterial Microbiota in the Digestive Tract of Triatomines.Reply to "Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs".CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM).Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease.4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.Identification of di-substituted ureas that prevent growth of trypanosomes through inhibition of translation initiation.3-pyridyl inhibitors with novel activity against Trypanosoma cruzi reveal in vitro profiles can aid prediction of putative cytochrome P450 inhibition.Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice.Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure.Phenotypic diversity and drug susceptibility of Trypanosoma cruzi TcV clinical isolatesClinical and veterinary trypanocidal benzoxaboroles target CPSF3
P2860
Q28547217-78CFF96E-3100-4103-BADA-E5FDFB98F2C2Q30487641-A973B726-E240-42D2-B652-23C6111DA7A4Q33743694-9125CE0E-309B-4E8E-B45B-E8C1BD987249Q34614864-DBB0B018-FC99-49D1-98B7-10DC4B510BE3Q34622554-9B9E0E64-111C-489B-810B-8F33305888B7Q35301205-C78899AA-5202-48A7-B8EA-C4A6F06ED7C5Q35333873-10BE9EF2-2F19-4799-8E6B-29DC6892A463Q35607812-7B2CD9D7-707E-4B9A-B285-5FD370E4EA59Q35607848-EB4FB6F6-FE70-4E1F-BD9D-42315106D54DQ35859935-3F42474C-2AEF-48C4-81B7-4B190A6715C4Q36000826-31DE085C-0C07-477D-9173-4085021ED11FQ36693033-E906AD1A-D76A-406B-8C8D-CE2873D6A32BQ37717875-12F02A50-C988-481A-BF2D-1448E2A4470BQ38253281-FEE06CE4-26F3-48EB-8F2C-64DCE3513DC8Q38695331-843BA02D-8D4B-453F-ABA3-92E967E80064Q38760667-5FDCABF2-9C69-4723-85EC-8AD85001BC5CQ38770142-A8FD6D32-65AA-4F30-814D-CCAB647D0E9CQ38777214-28C4F51F-B3C4-4AE7-BA47-2C4BA401A27DQ38920814-6044B930-B7F2-4A02-85A0-FF1CB9683A4BQ38929035-4D939773-7AAC-4671-9856-8CFA977AB705Q39010376-248C321C-8900-4816-9B8C-D42B55D68083Q39168166-15E4E9E0-A378-4413-A572-D20D825105C1Q40389286-ACB98753-1D40-4826-8745-1669689A0971Q41073713-C3B54A61-C507-493E-B447-486252DBD214Q41989175-6B173431-B5A6-42E4-85EE-A1F280BAC68AQ42287381-F1BFBDD4-CFC2-4313-B72D-EEFED85E5F98Q42625178-651BF144-E630-4378-9A22-F7B91AC84BD3Q47239192-0F94B85E-3A9E-4068-B039-DBC9A647B5F5Q47719317-CD32BC21-14CB-433A-A2BE-3289E1020C30Q48342608-4A68FE57-4811-4A1E-AAC5-5E022CC2BDB2Q51732698-C0F0FD2B-43D8-40D7-A288-C260D654CA4CQ52646076-8E9DB25F-3092-40C4-B489-C727B4A93B2AQ52648078-7FD4158E-A1EE-4B95-BCC5-E08CC0176C3EQ54248570-404A3A80-455F-45EF-B344-9E791E997640Q58763634-343DDE01-171B-4882-96CB-62A81D7143E7Q58842203-D657D67A-5272-4B80-A8D7-6EB9F93DC63C
P2860
Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 April 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nitroheterocyclic compounds ar ...... rug discovery and development.
@en
Nitroheterocyclic compounds ar ...... rug discovery and development.
@nl
type
label
Nitroheterocyclic compounds ar ...... rug discovery and development.
@en
Nitroheterocyclic compounds ar ...... rug discovery and development.
@nl
prefLabel
Nitroheterocyclic compounds ar ...... rug discovery and development.
@en
Nitroheterocyclic compounds ar ...... rug discovery and development.
@nl
P2093
P2860
P356
P1433
P1476
Nitroheterocyclic compounds ar ...... rug discovery and development.
@en
P2093
Adalberto M Araujo-Junior
Caio H Franco
Carolina B Moraes
Eric Chatelain
Hwayoung Kim
Lucio H Freitas-Junior
Miriam A Giardini
P2860
P2888
P356
10.1038/SREP04703
P407
P577
2014-04-16T00:00:00Z